Cross Linking for Progressive Keratoconus

♪ If you have been having
troublesome vision problems that interfere with the way you
see the world your doctor may have mentioned
the condition “Keratoconus”,
or KC. KC is a progressive eye disorder
that usually appears in people
in their teens or early 20s KC impacts the cornea, the
dome shaped, clear covering
on the front of your eye that bends light so it can
properly focus on images. In people with KC, the
cornea weakens and thins
over time, causing a cone-like bulge
to form. This can result in significant
visual loss and, in severe cases, the need
for a corneal transplant. The good news is that there
is now an FDA- approved therapy that can treat
progressive keratoconus. Called “Corneal Cross-linking”,
this minimally invasive, outpatient procedure combines
the use of specially formulated Vitamin B2 eye drops, called Photrexa & Photrexa Viscous, plus ultraviolet light from the KXL System.
Corneal cross-linking stiffens
and strengthens the cornea that has been weakened by
disease. The procedure takes about an
hour. Typically you will be awake during the treatment.
You will be given relaxing medication and numbing eye
drops. Then the thin layer on the
surface of the cornea,
called the epithelium, will be gently and temporarily
removed. Photrexa Viscous eye drops
will be placed in your eye
for at least 30 minutes Depending on the thickness of
your cornea, Photrexa
drops may also be required. The cornea is then exposed to
ultraviolet light for another
30 minutes while additional Photrexa
Viscous drops are applied. After the procedure, you
may experience some
sensitivity to light and have a foreign body
sensation. Without treatment, keratoconus
may cause your vision to
deteriorate, sometimes rapidly. Cross-linking is not intended to
improve your eyesight, but can
prevent it from getting worse. If you have been diagnosed with
KC, talk to your doctor. to see if corneal cross-linking
is right for you. You can find a list of doctors
who are familiar with keratoconus and cross-linking
at Avedro’s corneal cross linking
procedure is the FIRST and ONLY
therapeutic solution to receive FDA approval for the
treatment of progressive
keratoconus It offers an effective treatment
for patients who until recently had no therapeutic options
to limit progression of this
sight-threatening disease. The most common side effects
are haze, inflammation,
fine white lines, disruption of surface cells,
eye pain, reduced sharpness
of vision and blurred vision. Ulcerative keratitis, a
potentially serious eye
infection, can occur. Your doctor should monitor you
for resolution of epithelial
defects if they occur. These are not all the side
effects of corneal cross-
linking. The FDA-approved product
labeling can be found at You may report side effects
to the FDA at 1-800-FDA-1088. The safety and effectiveness
of corneal cross-linking has
not been established in pregnant women, women who
are breastfeeding, patients who
are less than 14 years of age and patients
65 years of age or older. Cross-linking is only performed
by specialists. And, Avedro’s corneal cross-linking procedure
is the ONLY FDA approved therapeutic solution for
treatment of this disease. You can find a doctor near you
through the locator tool link
on this website. ♪♪♪

Add a Comment

Your email address will not be published. Required fields are marked *